Key facts
- It has raised $7.7M; the latest was Seed Round ($3.3M) in Jun 2025.
- Notable investors include Club degli investitori, LIFTT, Vis Capital, B-Engine, Claris Ventures — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for ALKemist Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for ALKemist Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ALKemist Bio
Developer of cellular immunotherapies designed to target ALK-positive cancer cells through engineered T-cell receptors. The company's platform utilizes a process that extracts, modifies and reinfuses T cells from patients, enabling individuals to get effective treatment with specific oncogene-driven malignancies and aiming to improve patient outcomes in oncology.
- Sector
- Healthcare
- HQ
- Turin, Italy
- Founded
- 2023
- Employees
- 5
- Website
- alkemistbio.com/
- Ownership
- Privately Held (backing)
ALKemist Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ALKemist Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ALKemist Bio in its N-PORT filings yet. We sweep new filings monthly.